Cathepsin K is involved in development of psoriasis-like skin lesions through TLR-dependent Th17 activation

Journal of Immunology

Volumn 190, Issue 9, 2013, Pages 4805-4811

  Hirai, Toshitake ^a   Kanda, Takashi ^a   Sato, Kenji ^a   Takaishi, Mikiro ^a   Nakajima, Kimiko ^a   Yamamoto, Mayuko ^a   Kamijima, Reiko ^a   DiGiovanni, John ^b,c   Sano, Shigetoshi ^a  

^a KOCHI MEDICAL SCHOOL   (Japan)

^b UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^c The University of Texas at Austin   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPSORIASIS AGENT; CATHEPSIN K; CYTOKINE; INTERLEUKIN 12; INTERLEUKIN 23; MESSENGER RNA; NC 2300; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 7; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CATHEPSIN GENE; CATHEPSIN K GENE; CLINICAL ARTICLE; CONTROLLED STUDY; DENDRITIC CELL; DOWN REGULATION; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN TISSUE; IN VITRO STUDY; INTERLEUKIN 23 GENE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSORIASIS; SKIN DEFECT; T LYMPHOCYTE ACTIVATION; TH17 CELL;

ANIMALS; BONE MARROW; CATHEPSIN K; DERMIS; DOWN-REGULATION; EPIDERMIS; FEMALE; HUMANS; INTERLEUKIN-12; INTERLEUKIN-23; MALE; MICE; MICE, INBRED C57BL; MYELOID CELLS; PSORIASIS; RNA, MESSENGER; TH17 CELLS; TOLL-LIKE RECEPTOR 7; TOLL-LIKE RECEPTOR 8;

EID: 84876784030     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1200901     Document Type: Article

References (37)

1. Schön, M. P., and W. H. Boehncke. 2005. Psoriasis. N. Engl. J. Med. 352: 1899-1912. (Pubitemid 40627816)
2. Krueger, G. G., R. G. Langley, C. Leonardi, N. Yeilding, C. Guzzo, Y. Wang, L. T. Dooley, and M. Lebwohl; CNTO 1275 Psoriasis Study Group. 2007. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N. Engl. J. Med. 356: 580-592. (Pubitemid 46220818)
3. Leonardi, C. L., A. B. Kimball, K. A. Papp, N. Yeilding, C. Guzzo, Y. Wang, S. Li, L. T. Dooley, and K. B. Gordon; PHOENIX 1 Study Investigators. 2008. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, doubleblind, placebo-controlled trial (PHOENIX 1). Lancet 371: 1665-1674. (Pubitemid 351671883)
4. Haider, A. S., M. A. Lowes, M. Suárez-Fariñas, L. C. Zaba, I. Cardinale, A. Khatcherian, I. Novitskaya, K. M. Wittkowski, and J. G. Krueger. 2008. Identification of cellular pathways of "type 1, " Th17 T cells, and TNF-and inducible nitric oxide synthase-producing dendritic cells in autoimmune inflammation through pharmacogenomic study of cyclosporine A in psoriasis. J. Immunol. 180: 1913-1920.
5. Zaba, L. C., I. Cardinale, P. Gilleaudeau, M. Sullivan-Whalen, M. Suárez-Fariñas, J. Fuentes-Duculan, I. Novitskaya, A. Khatcherian, M. J. Bluth, M. A. Lowes, and J. G. Krueger. 2007. Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J. Exp. Med. 204: 3183-3194.
6. Lande, R., J. Gregorio, V. Facchinetti, B. Chatterjee, Y. H. Wang, B. Homey, W. Cao, Y. H. Wang, B. Su, F. O. Nestle, et al. 2007. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature 449: 564-569. (Pubitemid 47525141)
7. Ganguly, D., G. Chamilos, R. Lande, J. Gregorio, S. Meller, V. Facchinetti, B. Homey, F. J. Barrat, T. Zal, and M. Gilliet. 2009. Self-RNA-antimicrobial peptide complexes activate human dendritic cells through TLR7 and TLR8. J. Exp. Med. 206: 1983-1994.
8. Hollox, E. J., U. Huffmeier, P. L. Zeeuwen, R. Palla, J. Lascorz, D. Rodijk-Olthuis, P. C. van de Kerkhof, H. Traupe, G. de Jongh, M. den Heijer, et al. 2008. Psoriasis is associated with increased b-defensin genomic copy number. Nat. Genet. 40: 23-25.
9. Turk, V., B. Turk, and D. Turk. 2001. Lysosomal cysteine proteases: facts and opportunities. EMBO J. 20: 4629-4633. (Pubitemid 32848615)
10. Honey, K., and A. Y. Rudensky. 2003. Lysosomal cysteine proteases regulate antigen presentation. Nat. Rev. Immunol. 3: 472-482. (Pubitemid 37339187)
11. Villadangos, J. A., R. A. Bryant, J. Deussing, C. Driessen, A. M. Lennon-Duménil, R. J. Riese, W. Roth, P. Saftig, G. P. Shi, H. A. Chapman, et al. 1999. Proteases involved in MHC class II antigen presentation. Immunol. Rev. 172: 109-120. (Pubitemid 30000473)
12. Saftig, P., E. Hunziker, O. Wehmeyer, S. Jones, A. Boyde, W. Rommerskirch, J. D. Moritz, P. Schu, and K. von Figura. 1998. Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice. Proc. Natl. Acad. Sci. USA 95: 13453-13458. (Pubitemid 28522993)
13. Asagiri, M., T. Hirai, T. Kunigami, S. Kamano, H. J. Gober, K. Okamoto, K. Nishikawa, E. Latz, D. T. Golenbock, K. Aoki, et al. 2008. Cathepsin K-dependent Toll-like receptor 9 signaling revealed in experimental arthritis. Science 319: 624-627. (Pubitemid 351197065)
14. Sano, S., K. S. Chan, S. Carbajal, J. Clifford, M. Peavey, K. Kiguchi, S. Itami, B. J. Nickoloff, and J. DiGiovanni. 2005. Stat3 links activated keratinocytes and immunocytes required for development of psoriasis in a novel transgenic mouse model. Nat. Med. 11: 43-49. (Pubitemid 40215836)
15. Miyoshi, K., M. Takaishi, K. Nakajima, M. Ikeda, T. Kanda, M. Tarutani, T. Iiyama, N. Asao, J. DiGiovanni, and S. Sano. 2011. Stat3 as a therapeutic target for the treatment of psoriasis: a clinical feasibility study with STA-21, a Stat3 inhibitor. J. Invest. Dermatol. 131: 108-117.
16. Nakajima, K., T. Kanda, M. Takaishi, T. Shiga, K. Miyoshi, H. Nakajima, R. Kamijima, M. Tarutani, J. M. Benson, M. M. Elloso, et al. 2011. Distinct roles of IL-23 and IL-17 in the development of psoriasis-like lesions in a mouse model. J. Immunol. 186: 4481-4489.
17. Sano, S., K. S. Chan, M. Kira, K. Kataoka, S. Takagi, M. Tarutani, S. Itami, K. Kiguchi, M. Yokoi, K. Sugasawa, et al. 2005. Signal transducer and activator of transcription 3 is a key regulator of keratinocyte survival and proliferation following UV irradiation. Cancer Res. 65: 5720-5729. (Pubitemid 40911175)
18. Desmarais, S., F. Massé, and M. D. Percival. 2009. Pharmacological inhibitors to identify roles of cathepsin K in cell-based studies: a comparison of available tools. Biol. Chem. 390: 941-948.
19. Kawada, A., K. Hara, E. Kominami, M. Hiruma, H. Noguchi, and A. Ishibashi. 1997. Processing of cathepsins L, B and D in psoriatic epidermis. Arch. Der-matol. Res. 289: 87-93. (Pubitemid 27075573)
20. Schönefuss, A., W. Wendt, B. Schattling, R. Schulten, K. Hoffmann, M. Stuecker, C. Tigges, H. Lübbert, and C. Stichel. 2010. Upregulation of ca-thepsin S in psoriatic keratinocytes. Exp. Dermatol. 19: e80-e88.
21. Lee, E., W. L. Trepicchio, J. L. Oestreicher, D. Pittman, F. Wang, F. Chamian, M. Dhodapkar, and J. G. Krueger. 2004. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J. Exp. Med. 199: 125-130. (Pubitemid 38076484)
22. Asagiri, M., and H. Takayanagi. 2007. The molecular understanding of osteo-clast differentiation. Bone 40: 251-264.
23. Costa, A. G., N. E. Cusano, B. C. Silva, S. Cremers, and J. P. Bilezikian. 2011. Cathepsin K: its skeletal actions and role as a therapeutic target in osteoporosis. Nat. Rev. Rheumatol. 7: 447-456.
24. Rünger, T. M., M. J. Quintanilla-Dieck, and J. Bhawan. 2007. Role of cathepsin K in the turnover of the dermal extracellular matrix during scar formation. J. Invest. Dermatol. 127: 293-297. (Pubitemid 46106904)
25. Kitamura, H., H. Kamon, S. Sawa, S. J. Park, N. Katunuma, K. Ishihara, M. Murakami, and T. Hirano. 2005. IL-6-STAT3 controls intracellular MHC class II alphabeta dimer level through cathepsin S activity in dendritic cells. Immunity 23: 491-502. (Pubitemid 41587889)
26. Pedersen, T. X., C. Leethanakul, V. Patel, D. Mitola, L. R. Lund, K. Danø, M. Johnsen, J. S. Gutkind, and T. H. Bugge. 2003. Laser capture microdissection-based in vivo genomic profiling of wound keratinocytes identifies similarities and differences to squamous cell carcinoma. Oncogene 22: 3964-3976. (Pubitemid 36819670)
27. Yu, W., J. Liu, M. A. Shi, J. Wang, M. Xiang, S. Kitamoto, B. Wang, G. K. Sukhova, G. F. Murphy, G. Orasanu, et al. 2010. Cystatin C deficiency promotes epidermal dysplasia in K14-HPV16 transgenic mice. PLoS One 5: e13973.
28. Aranami, T., and T. Yamamura. 2008. Th17 cells and autoimmune encephalo-myelitis (EAE/MS). Allergol. Int. 57: 115-120. (Pubitemid 351897665)
29. Nizet, V., T. Ohtake, X. Lauth, J. Trowbridge, J. Rudisill, R. A. Dorschner, V. Pestonjamasp, J. Piraino, K. Huttner, and R. L. Gallo. 2001. Innate antimicrobial peptide protects the skin from invasive bacterial infection. Nature 414: 454-457. (Pubitemid 34173727)
30. Rosenberger, C. M., R. L. Gallo, and B. B. Finlay. 2004. Interplay between antibacterial effectors: a macrophage antimicrobial peptide impairs intracellular Salmonella replication. Proc. Natl. Acad. Sci. USA 101: 2422-2427. (Pubitemid 38269327)
31. Ong, P. Y., T. Ohtake, C. Brandt, I. Strickland, M. Boguniewicz, T. Ganz, R. L. Gallo, and D. Y. Leung. 2002. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N. Engl. J. Med. 347: 1151-1160.
32. Pütsep, K., G. Carlsson, H. G. Boman, and M. Andersson. 2002. Deficiency of antibacterial peptides in patients with morbus Kostmann: an observation study. Lancet 360: 1144-1149. (Pubitemid 35246490)
33. Ewald, S. E., B. L. Lee, L. Lau, K. E. Wickliffe, G. P. Shi, H. A. Chapman, and G. M. Barton. 2008. The ectodomain of Toll-like receptor 9 is cleaved to generate a functional receptor. Nature 456: 658-662.
34. Sepulveda, F. E., S. Maschalidi, R. Colisson, L. Heslop, C. Ghirelli, E. Sakka, A. M. Lennon-Duménil, S. Amigorena, L. Cabanie, and B. Manoury. 2009. Critical role for asparagine endopeptidase in endocytic Toll-like receptor signaling in dendritic cells. Immunity 31: 737-748.
35. Ewald, S. E., A. Engel, J. Lee, M. Wang, M. Bogyo, and G. M. Barton. 2011. Nucleic acid recognition by Toll-like receptors is coupled to stepwise processing by cathepsins and asparagine endopeptidase. J. Exp. Med. 208: 643-651.
36. Griffiths, C. E., B. E. Strober, P. van de Kerkhof, V. Ho, R. Fidelus-Gort, N. Yeilding, C. Guzzo, Y. Xia, B. Zhou, S. Li, et al; ACCEPT Study Group. 2010. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N. Engl. J. Med. 362: 118-128.
37. Nograles, K. E., and J. G. Krueger. 2011. Anti-cytokine therapies for psoriasis. Exp. Cell Res. 317: 1293-1300.